BestPractice Nordic has covered this year’s EHA, European Hematology Association, held from 9 - 12. JUNE 2022. We have published the most significant highlights within hematology as abstracts and articles. And once again, we have gathered the contributions of the leading researchers in a selection of MEDtalks and MEDcasts.
Here is a selection of the most important and discussed abstracts and articles regarding BestPractice Nordic’s coverage of EHA 2022.
Clinical and biological markers associated with long-term survival for patients with acute my eloid leukemia in remission after chemotherapy in the QUAZAR AML-001 trial of oral AZACITIDINE.
Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days
Late-breaking data from EHA 2022 present phase 2 results from the first multi-center ran domized trial comparing two chemotherapy regimens in Burkitt lymphoma (BL).
Chemoimmunotherapy (CIT) is still standard treatment for patients with chronic lymphocyt ic leukemia (CLL), particularly when favourable risk factors are present, although this treatment is not suitable for all patients due to the severe side effects. This study shows that targeted therapy combinations can improve PFS.
BestPractice Nordic has produced a number of MEDtalks in collaboration with some of the leading researchers in hematology, to present new knowledge and their latest results.
Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma
In this MEDtalk, Jean Marie Michot, MD, Paris, presents insights from poster S216 at EHA22, where a Cereblon E3 Ligase Modulator agent in monotherapy demostrate a showed a man ageable safety profile and promising efficacy in heavily pretreated patients with R/R NonHodgin Lymphoma.
Gut microbiome dysbiosis could be implicated in the pathogenesis of CLL
In this MEDtalk Tereza Faitova, Ph.D. fellow at Rigshospitalet DK, shed some light on that devi ation of the gut microbiome from homeostasis, distinguishes patients with CLL from the back ground populationthe. As CLL represents an antigen-driven malignancy with immune dys function, the gut microbiome could be impli cated in both the pathogenesis of CLL through an antigenic drive and contribute to the distor tion of the immune system.
In this MEDtalk, Frederik Schjesvold, Head of Oslo Myeloma Center in Norway, sums up the three lines of treatment options for transplant-ineligi ble patients with multiple myeloma. In the first line there is a clear first choice, depending on reimbursement. In the second-line the treat ment option depends on what the patient re ceived in the first line. The third line regimen is more complex because there are some added options, and the choice depends on what treat ment regimen was chosen for first and second line. See the MEDtalk and get all the details in the sequencing and treatment lines.
In this MEDtalk Anette Lodvir Hemsing, Leukemia Group at Haukeland University Hospital, Ber gen, presents the results of Rac1 inhibition of cell samples from 79 patients with AML. This study, illuminates inhibition of RAS relat ed C3 botulinum toxin substrate 1, Rac1, on cell samples from patients with AML. Rac1 is a GT Pase signal molecule which is overrepresented in several solid cancers and leukemia and has a role in migration, adhesion, and proliferation of the malign cells.